ARTEGENE
D20180302
Phase 2 small_molecule active
Quick answer
ARTEGENE for Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C) is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active